Overview
Somaxon Pharmaceuticals is a growing specialty pharmaceutical company dedicated to commercializing proprietary branded prescription therapeutics to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction. The company currently is focusing on in-licensing, developing and marketing proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area.
Silenor® is the company’s lead marketed product. Silenor is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance, and has been commercially available by prescription in the United States since September 2010 when it was launched in collaboration with Somaxon’s co-promotion partner Procter & Gamble. Somaxon is focusing its commercial efforts on Silenor while simultaneously evaluating other product candidates to fully leverage its growing sales infrastructure.
For more information on Silenor, please visit www.silenor.com.
Somaxon Pharmaceuticals is publicly traded on The NASDAQ Stock Market under the ticker symbol SOMX. For more investor information, please visit investors.somaxon.com.
Silenor is a prescription sleep medicine that is used to treat people with insomnia who have trouble staying asleep.
IMPORTANT SAFETY INFORMATION
Call your doctor if your insomnia worsens or is not better within 7 to 10 days. This may mean that there is another condition causing your sleep problem.
Be sure that you are able to devote 7 to 8 hours to sleep before being active again. Silenor should be taken within 30 minutes of bedtime. Do not take with alcohol or with other medicines that can make you sleepy. If you are on a monoamine oxidase inhibitor (MAOI) or have taken a MAOI within the past two weeks, you should not take Silenor. You should not take Silenor if you have an eye problem called narrow angle glaucoma that is not being treated, if you have severe urinary retention, or if you are allergic to any of the ingredients in Silenor. You should not drive or operate machinery at night after taking Silenor. Until you know how you will react to Silenor, you should be careful in performing such activities during the day following taking Silenor. Before you take Silenor, tell your doctor if you have a history of depression, mental illness or suicidal thoughts. You should call your doctor right away if after taking Silenor you walk, drive, eat or engage in other activities while asleep. Drowsiness is the most common adverse event observed in clinical trials. For more information, please see the complete Prescribing Information, including the Medication Guide.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
The product information provided in this site is intended only for residents of the United States. The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.
SIL-0214.P2A
